return to news
  1. Marksans Pharma share price jumps nearly 4% on acquisition of German pharma company ABCnow Gmbh

Market News

Marksans Pharma share price jumps nearly 4% on acquisition of German pharma company ABCnow Gmbh

WhatsApp Image 2025-01-20 at 11.25.23.jpeg

2 min read | Updated on July 08, 2026, 11:43 IST

SUMMARY

ABCnow GmbH is a foreign company registered in Germany. It is a pharmaceutical wholesale and distribution company headquartered in Flensburg, Germany. It is primarily engaged in marketing & distribution of OTC products in Germany

Stock list

MARKSANS
--
Marksan Pharma.jpg

Marksans Pharma shares rose nearly 50% in 2026.

Shares of Marksans Pharma jumped nearly 4% after the company announced acquisition of Germany based pharmaceutical company. The shares traded at ₹270 apiece on the NSE at 11:00 am in the morning. The shares made an intraday high of ₹272 apiece on the NSE.

Open FREE Demat Account within minutes!
Join now

The company in their exchange filing announced hat Marksans Pharma Limited has entered into a definitive agreement to acquire 100% of the share capital of ABCnow GmbH, a Germany based pharmaceutical company with frontend sales, marketing, and distribution capabilities across German healthcare market.

The acquisition will give Marksans Pharma access to regulated European markets and strengthening its forward-integration strategy through owned-market access capabilities in the European Union. The European market is second largest revenue contributor for the FY26 at 34%.

ABCnow GmbH is a foreign company registered in Germany. It is a pharmaceutical wholesale and distribution company headquartered in Flensburg, Germany. It is primarily engaged in marketing & distribution of OTC products in Germany. It has a turnover of € 227,233.69 as on December 31, 2025. It was incorporated in the year 2023 and it achieved revenue of € 510,215.60 in 2024 and € 227,233.69 in 2025.

This acquisition will enable Marksans to use the front-end sales and marketing infrastructure of ABCnow GmbH for marketing its products manufactured in India, UK, and USA regions. It will bolster Marksans’ presence in the European markets. The acquisition is expected to be completed by 31st July 2026. The company will acquire 100% stake with cash consideration of €892,384 (~₹9.7 crore).

The pharmaceutical player has delivered superior returns in 2026 as the shares rose over 50% on a YTD basis.

During the FY26, the company delivered highest-ever revenue at ₹3,000 crore, EBITDA of ₹601 crore and profit after tax of ₹420 crore. The company maintained its net-cash position of ₹990 crore, extending its mult-year track record.

About The Author

WhatsApp Image 2025-01-20 at 11.25.23.jpeg
Rohan Takalkar is a senior writer at Upstox and a seasoned capital markets analyst with over 10 years of experience. He is passionate about writing on equities, global markets, and the economy.

Next Story